Enlivex Therapeutics Ltd. News, Enlivex Therapeutics Ltd. Quote, ENLV Quote

Enlivex Therapeutics Ltd. (NQ:ENLV) Delayed: 1.32 -0.08 (5.71%)

Prev. Close

$1.40

Open

$1.36

52 Wk High

$0.94

52 Wk Low

$0.47

Day High

$1.39

Day Low

$1.32

P/E

N/A

EPS

$-0.11

Volume

63,434

Friends, Peers and Foes (?): MDWD (more...)

Apr 16, 2024 08:03 AM Form 6-K Enlivex Therapeutics For: Apr 16
Apr 11, 2024 02:58 PM Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis
Apr 11, 2024 08:14 AM Form 6-K Enlivex Therapeutics For: Apr 11
Apr 11, 2024 08:06 AM Enlivex Therapeutics Ltd. (ENLV) Reports Topline Results of Phase 2 Trial of Allocetra
Apr 11, 2024 08:05 AM Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
Mar 29, 2024 04:30 PM Form 6-K Enlivex Therapeutics For: Mar 29
Mar 22, 2024 10:52 AM Enlivex Therapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Feb 26, 2024 08:32 AM Enlivex Receives Regulatory Authorization From Israel’s Health Ministry For The Initiation Of Phase 1/2 Trial Evaluating Allocetra In Patients With Knee Osteoarthritis
Feb 21, 2024 08:32 AM Enlivex Completes Enrollment Of All 120 Patients In Phase 2 Trial Of Allocetra In Patients With Sepsis, Third-Leading Cause Of Mortality In US Hospitals
Feb 7, 2024 08:02 AM Form 6-K Enlivex Therapeutics For: Feb 07

Entities mentioned with ENLV